VRTX - VERTEX PHARMACEUTICALS INC / MA
486.43
-0.570 -0.117%
Share volume: 12,748
Last Updated: Wed 05 Feb 2025 03:30:09 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.61%
PREVIOUS CLOSE
CHG
CHG%
$487.00
-0.57
-0.12%
Fundamental analysis
69%
Profitability
95%
Dept financing
7%
Liquidity
64%
Performance
60%
Performance
5 Days
4.46%
1 Month
19.82%
3 Months
-3.52%
6 Months
1.13%
1 Year
12.45%
2 Year
58.19%
Key data
Stock price
$486.43
DAY RANGE
$484.06 - $488.13
52 WEEK RANGE
$377.85 - $519.88
52 WEEK CHANGE
$15.08
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Reshma Kewalramani
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.
Recent news